Intellectual Property Law
New Matter SPRING 2022, VOLUME 47, EDITION 1
Content
- 2022 New Matter Author Submission Guidelines
- A Look At the Trademark Modernization Act - One Year In
- Andy Warhol Foundation V. Goldsmith Redux
- INTELLECTUAL PROPERTY SECTION Executive Committee 2021-2022
- INTELLECTUAL PROPERTY SECTION Interest Group Representatives 2021-2022
- INTELLECTUAL PROPERTY SECTION New Matter Editorial board
- Letter From the Chair
- Letter From the Editor-in-chief
- McLe Trademark Law's Protection For Image and Likeness ... At Least If You're Famous
- Miramax's Lawsuit Against Quentin Tarantino May Set Precedent For Classification of Nfts
- Ninth Circuit Report
- Online Cle For Participatory Credit
- Quarterly International Ip Law Update
- Table of Contents
- The California Lawyers Association Intellectual Property Alumni
- The Licensing Corner
- Trade Secret Report
- Ttab Decisions and Developments
- Biogen Ma Inc. V. Emd Serono, Inc.
BIOGEN MA INC. V. EMD SERONO, INC.
D. Benjamin Borson
Borson Law Group P.C.
Biogen MA Inc. v. EMD Serono, Inc., United States Court of Appeals for the Federal Circuit, 976 F.3d 1326 (2020).
BACKGROUND
Biogen MA, Inc. ("Biogen") is the owner of U.S. Patent No. 7,588,755 (the "’755" patent), drawn to methods for treating viral diseases using recombinant interferon-ß. EMD Serono, Inc. ("Serono") sold a competing product, "Rebif" for treating multiple sclerosis (MS).